Brokers Set Expectations for Nuvation Bio FY2026 Earnings

Nuvation Bio Inc. (NYSE:NUVB) – HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Nuvation Bio in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.36) per share for the year, down from their previous forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2026 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.04) EPS and Q4 2027 earnings at ($0.02) EPS.

Nuvation Bio (NYSE:NUVB) last posted its earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $31.69 million for the quarter, compared to analyst estimates of $27.03 million. Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%.

Several other equities research analysts have also issued reports on the stock. Truist Financial increased their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Royal Bank Of Canada lifted their target price on shares of Nuvation Bio from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a research report on Thursday, July 23rd. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Nuvation Bio Trading Down 0.5%

Shares of NUVB stock opened at $6.57 on Tuesday. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -14.93 and a beta of 1.52. The company has a quick ratio of 8.14, a current ratio of 8.37 and a debt-to-equity ratio of 0.96. Nuvation Bio has a fifty-two week low of $2.18 and a fifty-two week high of $9.75. The firm’s 50 day moving average price is $5.79 and its two-hundred day moving average price is $5.24.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Rangeley Capital LLC purchased a new position in Nuvation Bio in the second quarter valued at about $25,000. Parallel Advisors LLC raised its position in shares of Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Nuvation Bio during the second quarter worth about $29,000. Captrust Financial Advisors bought a new position in Nuvation Bio during the second quarter worth $32,000. Finally, KBC Group NV acquired a new position in Nuvation Bio in the first quarter worth $37,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Insider Activity

In other news, Director Robert Mashal purchased 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average price of $4.73 per share, with a total value of $118,250.00. Following the purchase, the director directly owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. This represents a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stacy Markel sold 125,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total transaction of $753,750.00. Following the completion of the transaction, the insider owned 32,591 shares in the company, valued at $196,523.73. This represents a 79.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 235,668 shares of company stock valued at $1,419,495 in the last 90 days. Company insiders own 30.11% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.